Head to Head Review: Regeneron Pharmaceuticals (NASDAQ:REGN) & Absci (NASDAQ:ABSI)
by Michael Walen · The Markets DailyRegeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Absci (NASDAQ:ABSI – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.
Analyst Recommendations
This is a breakdown of recent recommendations for Regeneron Pharmaceuticals and Absci, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Regeneron Pharmaceuticals | 0 | 9 | 21 | 1 | 2.74 |
| Absci | 1 | 0 | 11 | 0 | 2.83 |
Regeneron Pharmaceuticals currently has a consensus price target of $898.97, suggesting a potential downside of 3.93%. Absci has a consensus price target of $14.50, suggesting a potential upside of 52.17%. Given Absci’s stronger consensus rating and higher possible upside, analysts clearly believe Absci is more favorable than Regeneron Pharmaceuticals.
Insider & Institutional Ownership
83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.0% of Absci shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 10.5% of Absci shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Regeneron Pharmaceuticals and Absci”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Regeneron Pharmaceuticals | $14.34 billion | 6.72 | $4.50 billion | $45.29 | 20.66 |
| Absci | $2.80 million | 584.03 | -$115.18 million | ($0.80) | -11.91 |
Regeneron Pharmaceuticals has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Regeneron Pharmaceuticals has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.
Profitability
This table compares Regeneron Pharmaceuticals and Absci’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Regeneron Pharmaceuticals | 28.51% | 16.01% | 12.22% |
| Absci | -7,756.38% | -61.71% | -54.52% |
Summary
Regeneron Pharmaceuticals beats Absci on 10 of the 15 factors compared between the two stocks.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.